NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NET Power Inc. (NYSE: NPWR, NPWR.WS) between June 9, 2023 and March 7, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 17, 2025. SO WHAT: If you purchased NET Power securities during the Class Period you may be entitled to compensation without p ...

SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”), have until Monday, July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutic ...

Group 1 - A class action has been filed against Krispy Kreme, Inc. for allegedly misleading investors regarding its partnership with McDonald's [1] - The complaint claims that demand for Krispy Kreme products at McDonald's locations declined significantly after the initial marketing launch, impacting average sales [1] - Krispy Kreme reported a net revenue of $375.2 million for Q1 2025, a decline of 15.3%, and a net loss of $33.4 million compared to a net loss of $6.7 million in the prior year [2] Group 2 - The company announced it is reassessing its deployment schedule with McDonald's and has withdrawn its prior full-year outlook due to uncertainty around the partnership [2] - Following the financial results announcement, Krispy Kreme's share price fell by nearly 25%, negatively affecting investors [2] - Shareholders interested in participating in the class action must file their papers by July 15, 2025, to serve as lead plaintiff [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Treace Medical Concepts, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6]. - The lawsuit claims that Treace Medical made false or misleading statements regarding its business operations and the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been recognized for its performance in securities class action settlements [4].

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly making false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of Indiana on behalf of individuals and entities that purchased Elevance securities between April 18, 2024, and October 16, 2024 [1]. - Investors have until July 11, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Elevance - Defendants allegedly misrepresented their monitoring of cost trends related to the Medicaid redetermination process and assured investors that premium rates were sufficient to manage risks associated with Medicaid patients [3]. - The lawsuit claims that while Medicaid expenses were acknowledged to be rising, the true impact of the redetermination process was not adequately reflected in Elevance's financial guidance for 2024 [3]. - It is asserted that the acuity and utilization of Medicaid members increased significantly, as those removed from Medicaid were generally healthier than those who remained eligible [3]. Impact on Investors - The lawsuit contends that when the true details regarding the Medicaid redetermination process became public, investors suffered damages due to the misleading statements made by Elevance [3].

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) between August 8, 2024, to May 8, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Karthik Trichur Sundaram v. Iovance Biotherapeutics, Inc., et al. (Case No. 3:25-cv-04177) has been commenced in the United States Dist ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Doximity caused the company to misrepresent or fail to disclose material information concerning the Company’s business and operations. Specifically, the Complaint alleges Defendants repeatedly touted the Company’s business pro ...

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the proposed buyout of Dun & Bradstreet Holdings, Inc. (DNB) by Clearlake Capital Group at a price of $9.15 per share, questioning whether shareholders are receiving adequate compensation and if there were any breaches of fiduciary duties by the company's officers or directors [1][3]. Summary by Sections Buyout Details - On March 24, 2025, DNB announced an agreement to be acquired by Clearlake Capital at a cash price of $9.15 per share, resulting in current stockholders being cashed out and the company's shares ceasing to be publicly traded [2]. Investigation Focus - The investigation aims to assess if DNB shareholders are receiving sufficient monetary consideration for their shares, especially considering that DNB's stock traded above $12.00 per share as recently as February 2025, and analysts had price targets above the buyout price at the time of the announcement [3]. Shareholder Communication - DNB shareholders are encouraged to contact Kaskela Law LLC for information regarding their legal rights and options related to the investigation [4].

NEW YORK, May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of SoundHound AI, Inc. (NASDAQ: SOUN) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at SoundHound caused the company to misrepresent or fail to disclose that (i) the material weaknesses in SoundHound's internal controls over financial reporting impaired the Company's ability to effectively account for corpora ...

NEW YORK, May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Neumora Therapeutics caused the company to misrepresent or fail to disclose (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial in ...